<DOC>
	<DOCNO>NCT02164955</DOCNO>
	<brief_summary>This registry prospective , multi-center , observational study collect safety data multiple myeloma adult patient receive least two prior therapy take IMNOVID ( pomalidomide ) part standard care . The registry remain open 500 patient receive least 3 cycle pomalidomide . All patient register follow prospectively 3 year follow end pomalidomide treatment . During time incidence second primary malignancy ( SPM ) , overall survival occurrence pregnancy assess .</brief_summary>
	<brief_title>A Post Authorisation Registry IMNOVID ( Pomalidomide ) Patients With Relapsed Refractory Multiple Myeloma .</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Understand voluntarily sign informed consent form , applicable , never previously treat pomalidomide inclusion Registry . Patients symptomatic , measurable relapse refractory multiple myeloma receive least two prior treatment regimen , include bortezomib lenalidomide demonstrate disease progression last therapy commence pomalidomide base treatment . Refusal participate Registry currently participate treatment phase interventional clinical trial . Pregnancy . Women childbearing potential , unless condition pregnancy prevention program meet . Male patient unable follow comply require contraceptive measure . Hypersensitivity active substance excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pomalidomide</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed , Refractory</keyword>
	<keyword>Observational</keyword>
	<keyword>Imnovid</keyword>
	<keyword>Registry</keyword>
	<keyword>Post-approval</keyword>
	<keyword>Safety</keyword>
</DOC>